Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · IEX Real-Time Price · USD
6.11
+0.04 (0.66%)
At close: Jul 19, 2024, 4:00 PM
6.05
-0.06 (-0.98%)
Pre-market: Jul 22, 2024, 7:23 AM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $177.60M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $47.46M. In the year 2023, Vanda Pharmaceuticals had annual revenue of $192.64M.
Revenue (ttm)
$177.60M
Revenue Growth
-30.81%
P/S Ratio
2.00
Revenue / Employee
$874,897
Employees
203
Market Cap
355.59M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
Dec 31, 2009 | 4.55M | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 33.98K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xeris Biopharma Holdings | 171.36M |
Talkspace | 162.13M |
Cartesian Therapeutics | 25.91M |
uniQure | 19.00M |
AC Immune | 16.82M |
TScan Therapeutics | 14.81M |
Q32 Bio | 354.00K |
VNDA News
- 21 days ago - Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex - PRNewsWire
- 25 days ago - Future Pak withdraws offer to buy Vanda Pharmaceuticals - Reuters
- 25 days ago - Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc. - Business Wire
- 4 weeks ago - Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 4 weeks ago - Vanda rejects Future Pak and Cycle Pharma's takeover offers - Reuters
- 4 weeks ago - Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders - PRNewsWire
- 5 weeks ago - Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98% - GlobeNewsWire
- 5 weeks ago - Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak - PRNewsWire